Diagnostic performance of gastrin-releasing peptide receptor-targeted positron-emission tomography in biochemically recurrent prostate cancer-a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
278 patients were finally included.
I · Intervention 중재 / 시술
full-text screening and 6 articles with 278 patients were finally included
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
[BACKGROUND] Gastrin-releasing peptide receptor (GRPR)-targeting radiopharmaceuticals are being developed for diagnostic and therapeutic applications in prostate cancer.
- 95% CI 0.25-0.51
- 연구 설계 systematic review
APA
Huang H, Huang Y, et al. (2026). Diagnostic performance of gastrin-releasing peptide receptor-targeted positron-emission tomography in biochemically recurrent prostate cancer-a systematic review and meta-analysis.. Quantitative imaging in medicine and surgery, 16(1), 11. https://doi.org/10.21037/qims-2025-1809
MLA
Huang H, et al.. "Diagnostic performance of gastrin-releasing peptide receptor-targeted positron-emission tomography in biochemically recurrent prostate cancer-a systematic review and meta-analysis.." Quantitative imaging in medicine and surgery, vol. 16, no. 1, 2026, pp. 11.
PMID
41522030 ↗
Abstract 한글 요약
[BACKGROUND] Gastrin-releasing peptide receptor (GRPR)-targeting radiopharmaceuticals are being developed for diagnostic and therapeutic applications in prostate cancer. This systematic review and meta-analysis aimed to synthesize available evidence regarding the diagnostic performance of GRPR-targeted positron-emission tomography (PET) in biochemically recurrent prostate cancer.
[METHODS] A comprehensive literature search was performed using appropriate keywords search strings formulated with Boolean syntax in the PubMed, Embase and Cochrane Library. Articles related to GRPR-targeted PET in biochemically recurrent prostate cancer were included, covering publications available up to May 1, 2025. A meta-analysis with a random-effects model was used to estimate overall and subgroup-specific pooled detection rate (DR). The literature quality was determined by the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. A sensitivity analysis using leave-one-out method was performed to evaluate the potential bias.
[RESULTS] Out of 469 articles, 212 underwent full-text screening and 6 articles with 278 patients were finally included. The overall DR of GRPR-targeted PET for biochemical recurrence (BCR) was 0.68 [95% confidence interval (CI): 0.6-0.75]. Four studies reported the pooled DRs stratified by serum prostate-specific antigen (PSA) levels: 0.38 (95% CI: 0.25-0.51) for PSA <0.5 ng/mL stratum, 0.69 (95% CI: 0.53-0.85) for PSA 0.5 to <1.0 ng/mL stratum, 0.61 (95% CI: 0.43-0.79) for PSA 1.0 to <2.0 ng/mL stratum, 0.75 (95% CI: 0.58-0.91) for PSA 2.0 to <5.0 ng/mL stratum, 0.72 (95% CI: 0.60-0.84) for PSA ≥5.0 ng/mL stratum, respectively.
[CONCLUSIONS] In the present meta-analysis, GRPR-targeted PET has comparable and promising diagnostic utility for BCR of prostate cancer compared to prostate-specific membrane antigen (PSMA) and conventional imaging. Nevertheless, the limited sample sizes of existing studies warrant large-sample prospective trials comparing GRPR-targeted PET with first-line modalities to validate its clinical diagnostic and therapeutic value.
[METHODS] A comprehensive literature search was performed using appropriate keywords search strings formulated with Boolean syntax in the PubMed, Embase and Cochrane Library. Articles related to GRPR-targeted PET in biochemically recurrent prostate cancer were included, covering publications available up to May 1, 2025. A meta-analysis with a random-effects model was used to estimate overall and subgroup-specific pooled detection rate (DR). The literature quality was determined by the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. A sensitivity analysis using leave-one-out method was performed to evaluate the potential bias.
[RESULTS] Out of 469 articles, 212 underwent full-text screening and 6 articles with 278 patients were finally included. The overall DR of GRPR-targeted PET for biochemical recurrence (BCR) was 0.68 [95% confidence interval (CI): 0.6-0.75]. Four studies reported the pooled DRs stratified by serum prostate-specific antigen (PSA) levels: 0.38 (95% CI: 0.25-0.51) for PSA <0.5 ng/mL stratum, 0.69 (95% CI: 0.53-0.85) for PSA 0.5 to <1.0 ng/mL stratum, 0.61 (95% CI: 0.43-0.79) for PSA 1.0 to <2.0 ng/mL stratum, 0.75 (95% CI: 0.58-0.91) for PSA 2.0 to <5.0 ng/mL stratum, 0.72 (95% CI: 0.60-0.84) for PSA ≥5.0 ng/mL stratum, respectively.
[CONCLUSIONS] In the present meta-analysis, GRPR-targeted PET has comparable and promising diagnostic utility for BCR of prostate cancer compared to prostate-specific membrane antigen (PSMA) and conventional imaging. Nevertheless, the limited sample sizes of existing studies warrant large-sample prospective trials comparing GRPR-targeted PET with first-line modalities to validate its clinical diagnostic and therapeutic value.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- A Machine Learning Approach to Predicting Donor Site Complications Following DIEP Flap Harvest.
- Umbilical Complications following DIEP Flap Breast Reconstruction: Demonstrating the Added Benefit of Preoperative Imaging.
- TAZ WW Domain-Mediated Regulation of Gluconeogenesis and Tumorigenesis in Hepatocellular Carcinoma through Interaction with the Glucocorticoid Receptor.
- Targeting the CCL5/CCR5-PI3K-AKT axis suppresses hepatic stellate cell-induced breast cancer metastasis.
- Decoding prostate cancer therapy resistance and novel therapeutic strategies.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Incidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy.
- Neoadjuvant androgen deprivation therapy with bicalutamide compared to hormonal agents in treating high-risk prostate cancer: a real-world cohort study.
- Predicting PD-L1 expression status in NSCLC using radiomic analysis of 18 F-FDG-PET/CT images.
- Construction of a survival model for predicting biochemical recurrence of prostate cancer based on propionate metabolism-related genes.
- Intermittent androgen deprivation therapy for biochemical recurrence or prostate-specific antigen (PSA) persistence after radical prostatectomy: efficacy and prognostic factors.
- Risk prediction models for biochemical recurrence of Chinese prostate cancer patients after radical prostatectomy based on magnetic resonance imaging examination: a systematic review.